https://www.selleckchem.com/pr....oducts/buloxibutid.h
The levels of IGF-1 and ROS are abnormally elevated in various tumor tissues, and IGF-1 has been reported to be associated with the development and progression of inflammation in cancers. In this study, we found that IGF-1 activated NF-κB and NLRP3 inflammatory signaling via IRS-1/mPGES-1/NOX2-regulated ROS. Additionally, in the B16-F10 tumor-bearing mouse model, the number of tumors, tumor growth, invasion of tissues, and expression of proinflammatory factors in peripheral blood were significantly decreased by treatment with an inh
Aimer
Commentaire
Partagez
